Job Search
What type of work do you want?
Where do you want to work?
Input the your postcode district and the distance you are prepared to travel
from
or Select a region
Manufacturing news in brief

Our periodic round-up of
developments in the pharmaceutical manufacturing sector reveals a
crop of facility news, with capital investments at Servier,
Aurobindo, PX'Therapeutics and QM Specials, a reprieve for Dey and
bad news for employees at a former Schering-Plough warehousing
unit.
Sanofi-Aventis has
agreed to participate in a Russian pilot project designed to
attract and retain pharmaceutical manufacturing in the country and
expand the overall pharmaceutical market. The French drugmaker said
it would contribute to the Pharmpolis Project via its
recently-opened insulin factory in Russia. Sanofi-Aventis signed
the memorandum of understanding
with Prominvest, a subsidiary of the
state-owned corporation Rostekhnologii during the Franco-Russian
Intergovernmental Seminar held in France on November 27.
Up to 50 jobs could be created at a
pharmaceutical manufacturing facility in Lismore, Ireland, operated
by QM Specials, a subsidiary of UK-based
Quantum Specials. The firm has been granted a license from the
Irish Medicines Board to produce a range of 'special' medicines.
These include bespoke medicines which are tailor made to meet the
requirements of patients, as well as drugs which have a product
license in the UK but not in Ireland.
French contract
manufacturer PX'Therapeutics SA says it will
set up of an additional biomanufacturing unit dedicated to the
production of therapeutic proteins and monoclonal antibodies in
mammalian cells at its site in Grenoble. The plant is due to be
operational from April 2010 and will allow cell banking as well as
preclinical and clinical manufacturing of biotherapeutics,
operating at the 100-200-litre scale, and the company also plans to
add an additional 100L bioreactor.
Dey LP has decided to
keep a plant in California, USA, open and retain a workforce of
300-400 at the unit. The facility was put forward for closure last
year after Mylan took over Dey, which specialises in generic
versions of respiratory drugs. At its height Dey's Napa operations
employed around 500 people.
Merck & Co has
decided to close down a warehousing facility in New Jersey, USA,
with the loss of up to 80 jobs. The facility in Upper Macungie,
Hunterdon County was formerly owned
by Schering-Plough, which was acquired by
Merck earlier this month. The site was primarily used to package
NuvaRing, a contraceptive device. The current workload will
transfer to a Merck facility in Kenilworth.
France's Servier
has officially opened a 47 million euro production facility in
County Wicklow, Ireland, that will create 100 jobs, according to
the Irish Development Agency. The new 4,500 sq. m. facility marks
the final stage in a 124 million euro investment process at the
site and has seen its size double in the last three years.
Indian active pharmaceutical ingredient
(API) producer Aurobindo has opened a new
formulations facility in Hyderabad which will help it boost
revenues to $2 billion by 2013, according to a PharmaAsiaNews
report. A wide-ranging agreement with Pfizer to provide generic
products in emerging and development markets will be another major
growth driver.